Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
Introduction: Synaptic dysfunction and degeneration is one of the earliest events in Alzheimer's disease (AD) and the best correlate of cognitive decline. Thus, identification and validation of biomarkers reflecting synaptic degeneration to be used as prognostic biomarkers are greatly needed.Method: Solid-phase extraction and parallel reaction monitoring mass spectrometry were used to quantify 17